For our R&D development, we are looking for investors (capital contribution) sharing our values and vision.

You can see our R&D programs here. Our next development is the ChimioFx’s clinical validation during 2 years with 3 Hospitals. The goal is to confirm the sensibility, the sensitivity and the robutness of the test before his commercialization in 2021.

Don’t hesitate to contact us for more information.

Diag2Tec’s Headquarters

Cap Omega, Rond-Point Benjamin Franklin
CS 39521
34960 Montpellier, France